Biosimilar Antibodies

Solrikitug is a human IgG1 κ monoclonal antibody targeting the cytokine receptor-like factor 2 (CRLF2). For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.

Idactamab (INT-001) is an IgG1-κ monoclonal antibody demonstrating significant in vivo activity against a range of hematological malignancies. This antibody serves as a precursor for the synthesis of MEDI7247, a highly potent and specific antibody-drug conjugate (ADC) that targets ASCT2 (SLC1A5), offering therapeutic potential in oncology research.

Dezamizumab (GSK 2398852) is a fully humanized recombinant monoclonal IgG1 antibody targeting the serum amyloid P component (SAP), exhibiting potential anti-amyloid activity. This antibody facilitates the immunotherapeutic clearance of amyloid deposits. It is primarily utilized in the study of Amyloid light-chain (AL) amyloidosis, providing a valuable tool for research into the pathogenesis and treatment of this condition.

The Anti-CD54/ICAM-1 Antibody (R6-5-D6) is a chimeric mouse monoclonal antibody of the IgG2a subclass, specifically designed to target human CD54, also known as ICAM-1. This antibody has been engineered for optimal binding specificity to ICAM-1, a critical molecule involved in inflammation and immune responses. For accurate experimental control, the recommended isotype control is Mouse IgG2a kappa, which serves as a non-reactive benchmark to help discern specific antibody interactions. This product is ideal for researchers studying cellular adhesion, immune response modulation, and ICAM-1 related pathways in various disease models.

IMMU-114 is a humanized monoclonal antibody targeting human leukocyte antigen-DR (HLA-DR). This antibody is designed to deplete antigen-presenting cells (APCs) and diminish the population of alloreactive T cells, making it a valuable tool for research in immunology and transplantation studies.

Felzartamab (MOR-202) is a human monoclonal antibody designed to specifically bind to CD38, a glycoprotein predominantly expressed on the surface of multiple myeloma cells. This antibody is utilized extensively in research focused on the pathophysiology and treatment strategies of multiple myeloma, offering a critical tool for investigating disease mechanisms and therapeutic interventions.

Vopikitug is a human monoclonal antibody of the IgG1-kappa isotype, specifically targeting the interleukin-2 receptor alpha subunit (IL-2RA), also known as TAC, p55, or CD25. This antibody exhibits antineoplastic activity, making it relevant for research in cancer immunotherapy and the modulation of immune responses.

Erfonrilimab (KN-046) is a bifunctional monoclonal antibody designed to simultaneously inhibit both PD-L1 and CTLA-4, two critical immune checkpoint proteins. This dual inhibition mechanism enhances the immune system's ability to recognize and destroy cancer cells, making it a promising therapeutic agent in oncology research. Erfonrilimab is specifically engineered for use in investigating the efficacy of combined checkpoint blockade in various cancer models.

Ingitamig is a bispecific antibody engineered to target TNFRSF17 and KLRK1. This dual-specificity is achieved through its (G1_L-κ)_(G1-scFvkh_L-κ) configuration, making it a versatile tool in the study of immune responses and potential therapeutic interventions.

Stamulumab (MYO-029) is a recombinant human IgG1λ antibody designed to selectively bind to myostatin, effectively neutralizing its activity. This inhibition is achieved by preventing myostatin from interacting with its high-affinity receptor, ActRIIB. The primary biological outcome observed with Stamulumab treatment is muscle fiber hypertrophy, rather than hyperplasia, as demonstrated in SCID mice studies. Given its mechanism of action, Stamulumab is a valuable tool for research into various muscular dystrophies, including Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD), offering potential insights into therapeutic strategies targeting muscle growth and repair.

Igovomab is a monoclonal antibody specifically designed for imaging applications in ovarian cancer research. This antibody targets antigens associated with ovarian cancer, facilitating the detailed study of disease pathology and aiding in the development of targeted therapies. Igovomab is utilized primarily in diagnostic research settings to improve the visualization and characterization of ovarian cancer tissues.

Simaravibart (MAD-0004J08) is an IgG1κ monoclonal antibody specifically designed to target the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) glycoprotein. This antibody binds with high specificity and affinity, making it an essential tool for research focused on the mechanisms of SARS-CoV-2 infection and immune response.

The Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) is a humanized monoclonal antibody, expressed in Chinese Hamster Ovary (CHO) cells, specifically designed to target CDH17, also known as Cadherin-17. This antibody is composed of an IgG1 heavy chain and a human kappa (huκ) light chain, with a molecular weight of approximately 149.12 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa. This product is essential for research focusing on the role of Cadherin-17 in cellular adhesion processes and its implications in gastrointestinal tract diseases and cancers.

Surovatamig is a bispecific antibody engineered to target CD3D, CD3E, and CD19. This antibody features a (H-γ4_L-κ)_VH-G4(h-CH2-CH3) structure, designed to engage both T cells and B cells for enhanced therapeutic efficacy. Surovatamig is utilized primarily in research focused on the mechanisms of immune response and potential therapeutic applications in immunotherapy. This product is pivotal for studies involving cell signaling and activation in immune cells, making it a valuable tool for investigations into novel cancer treatments and autoimmune disease therapies.

Amivantamab (JNJ-61186372) is a bispecific human antibody targeting EGFR and MET receptors, designed for its potent anticancer immune activity. This therapeutic antibody functions by inhibiting ligand binding, thereby promoting the endocytosis and subsequent degradation of receptor-antibody complexes. Furthermore, Amivantamab facilitates Fc-dependent cytokinesis in macrophages and enhances antibody-dependent cellular cytotoxicity in natural killer cells, making it a valuable tool in cancer immunotherapy research.

Vobarilizumab (ALX-0061) is a humanized bispecific monoclonal antibody that targets both the interleukin-6 receptor (IL-6R) and human serum albumin (ALB) with a dissociation constant (Kd) of 0.19 pM. This antibody features distinct domains: one that binds to IL-6R and another that binds to human serum albumin. The dual specificity of Vobarilizumab allows for enhanced targeting and retention in the human body, making it a valuable tool in the study of inflammatory autoimmune conditions, including rheumatoid arthritis. This antibody's unique configuration and high affinity make it ideal for research applications focused on the pathogenesis and treatment strategies of such diseases.

Blontuvetmab (AT 004) is a caninized monoclonal antibody targeting CD20, designed specifically for canine applications. It exhibits dual functionality by acting as a highly potent and selective antagonist of the A2aR receptor while also displaying weak agonistic activity towards the Nociceptin/Orphanin FQ receptor (NOP). This antibody effectively inhibits the activation of A2aR mediated by 5'-N-Ethylcarboxamidoadenosine (NECA), and it significantly counteracts the adenosine-induced suppression of CD8 T cell activation. This action leads to an increase in cytokine production, including IFN-γ. Blontuvetmab is primarily used in research focused on Canine B-cell lymphoma, offering a valuable tool for studying the modulation of immune responses in this condition.

Aldastotug is a human monoclonal antibody of the IgG1κ isotype designed to specifically target SIGLEC15. For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.

APX-007 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target the IL-6 receptor alpha (IL-6Ra/CD126). This antibody is comprised of a human IgG1 type heavy chain and a human kappa (huκ) type light chain, with an approximate molecular weight of 150 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.

Lemalesomab (IMMU-MN3) is a monoclonal antibody derived from mouse IgG1, specifically designed as a Fab' fragment targeting NCA-90. This antibody is utilized primarily in the study of inflammation, infectious lesions, and for the imaging of infections in research settings. Its specificity for NCA-90 makes it a valuable tool for detailed investigations into cellular processes associated with immune responses and microbial infection.

Dupilumab (REGN-668) is a fully human monoclonal antibody targeting the interleukin-4 receptor alpha (IL-4Rα). By inhibiting signaling pathways of both interleukin-4 (IL-4) and interleukin-13 (IL-13), this antibody has demonstrated significant efficacy in ameliorating the symptoms of moderate-to-severe atopic dermatitis. This specificity makes it a valuable tool for research into the pathophysiology and treatment of allergic and inflammatory diseases.

Aducanumab (BIIB037) is a human monoclonal antibody designed to selectively target aggregated forms of amyloid-beta (Aβ), a key pathological marker in Alzheimer’s disease (AD). Demonstrating effective penetration into brain tissue, Aducanumab is extensively utilized in the research of Alzheimer's disease mechanisms and potential therapies. This antibody is pivotal for studies focusing on the pathogenesis and treatment strategies of AD, providing essential insights into amyloid-beta dynamics and clearance in neural environments.

NGM-120 is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the Glial Cell line-Derived Neurotrophic Factor Family Receptor Alpha Like (GFRAL). This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 145.7 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended.

Semzuvolimab is a humanized IgG1κ monoclonal antibody specifically designed to target the p55 T cell surface antigen T4/Leu-3, commonly known as CD4. This antibody has demonstrated capabilities in neutralizing HIV infections and shows potential in inhibiting HIV infections that are stable under highly active antiretroviral therapy (HAART). Semzuvolimab offers significant utility in research focused on the immunological aspects of HIV management and therapy development.

Etentamig is a bispecific T-cell engager (BiTE) targeting both B-cell maturation antigen (BCMA) and the CD3 complex on T cells. This dual specificity enables Etentamig to simultaneously inhibit BCMA activity and activate the CD3 signaling pathway in T cells. It is primarily utilized in research focused on multiple myeloma and immunoglobulin light chain amyloidosis, with potential applications in exploring its effects on cardiovascular diseases. This makes Etentamig a valuable tool for advancing understanding of disease mechanisms and therapeutic strategies in these areas.

Zadoprubart is a humanized IgG4κ monoclonal antibody specifically targeting BTLA (B and T Lymphocyte Attenuator). For experimental control purposes, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This specificity and control recommendation ensure precise targeting and accurate data interpretation in research applications focusing on immune modulation.

Omodenbamab is a human monoclonal antibody that targets Staphylococcal protein A (SpA), a critical component of the Staphylococcus aureus cell wall. With a dissociation constant (KD) of 0.0467 nM, this antibody demonstrates high affinity for SpA, effectively disrupting a major S. aureus immune evasion strategy. Omodenbamab is primarily utilized in the investigation of S. aureus bloodstream infections, providing a valuable tool for research in microbial pathogenesis and immune response mechanisms.

The Anti-TNFSF2 / TNFa (ESBA 105) antibody specifically targets Tumor Necrosis Factor (TNF), a critical cytokine involved in systemic inflammation and the acute phase response. This antibody is characterized by its efficient intraocular penetration, reaching both the anterior and posterior regions of the eye, making it particularly useful in research studies focused on ocular diseases and inflammatory responses within the eye.

RG-6125 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target CDH11, also known as Cadherin-11. This antibody is comprised of a human IgG2 type heavy chain and a human kappa (huκ) type light chain, exhibiting a predicted molecular weight of 145 kDa. For experimental control purposes, Human IgG2 kappa, Isotype Control is recommended.

Cenzestotug is a monoclonal antibody that specifically targets the human Tumor Necrosis Factor Receptor Superfamily Member 4 (TNFRSF4). By binding to TNFRSF4, Cenzestotug activates key immune cells, demonstrating potent immunostimulatory and antitumor properties. This antibody holds significant potential for research in cancer immunotherapy, providing a valuable tool for investigating the modulation of immune responses in oncological studies.

Quisovalimab (AVTX-002; AEVI 002; SAR 252067) is a human monoclonal antibody designed to target LIGHT, a cytokine related to tumor necrosis factor (TNF) identified as TNFSF14. This cytokine is critically involved in the pathogenesis of acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS), particularly noted in COVID-19 cases. The therapeutic potential of Quisovalimab extends to its application in research focused on COVID-19-induced ARDS and related inflammatory conditions, providing a valuable tool for studies aimed at understanding and mitigating cytokine-mediated diseases.

Frunevetmab (NV-02) is a felinized monoclonal antibody targeting nerve growth factor (NGF) with a dissociation constant (Kd) of 20 pM, indicating high affinity for its antigen. This antibody has been shown to effectively reduce osteoarthritis-related pain in feline models, making it a valuable tool for research into pain management and degenerative joint diseases in cats.

Sifalimumab (MEDI-545) is a monoclonal antibody that targets and neutralizes multiple subtypes of interferon-alpha (IFNα), a key cytokine involved in the pathogenesis of autoimmune disorders. By binding to IFNα, Sifalimumab effectively suppresses abnormal immune responses. This antibody is particularly relevant for research into systemic lupus erythematosus (SLE), providing a valuable tool for investigating the role of IFNα in SLE pathophysiology and for exploring potential therapeutic interventions.

Imaprelimab (PRX-003) is a humanized IgG1κ monoclonal antibody targeting the melanoma cell adhesion molecule (MCAM). Classified as an antineoplastic agent, it is designed to interfere with MCAM-mediated processes, potentially inhibiting tumor growth and metastasis in melanoma and other cancers expressing MCAM. This antibody is utilized primarily in research focused on cancer biology and therapeutic development.

Anbenitamab (KN-026) is a bispecific antibody engineered to target extracellular domains II and IV of human HER2, effectively blocking both ligand-dependent and ligand-independent signaling pathways associated with this receptor. The inclusion of the IgG1 Fc fragment enhances its interaction with FcRγIIIa, facilitating robust antibody-dependent cell-mediated cytotoxicity (ADCC) and effectively inhibiting tumor cell proliferation. This antibody is primarily researched for its therapeutic potential in HER2-positive metastatic breast cancer (MBC).

The Anti-B7-H4/VTCN1 Antibody is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the B7-H4/VTCN1 antigen, a protein implicated in the regulation of immune response. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, and it has a predicted molecular weight of 145 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa. This product is ideal for use in research applications focusing on immune modulation and cancer immunotherapy.

Clesitamig is a humanized antibody designed to specifically target DLL3 (Delta-like ligand 3). This antibody features a variable light chain (V-κ) and a gamma 1 heavy chain (G4CH1-G1h-H-γ1), configured in a structurally optimized format to ensure high specificity and affinity for DLL3. Clesitamig is ideal for research focused on the role of DLL3 in cancer pathogenesis and therapy, particularly in the context of small cell lung cancer and other neuroendocrine tumors where DLL3 expression is prevalent.

Tidutamab (XmAb-18087) is a humanized, affinity-optimized bispecific antibody designed to target both the somatostatin receptor 2 (SSTR2) and the CD3 epsilon subunit of the T-cell receptor. This antibody features a complete Fc domain, which enhances its stability and prolongs its serum half-life. Tidutamab facilitates the elimination of SSTR2-expressing tumor cells through the mechanism of redirected T-cell-mediated cytotoxicity (RTcC), offering a targeted approach in cancer immunotherapy.

Sacituzumab is a humanized IgG1 monoclonal antibody that specifically targets Trophoblast cell surface antigen 2 (TROP2). This antibody binds to the linear epitopes of the TROP2 protein. Although Sacituzumab alone does not exhibit antitumor effects or inhibit the function of TROP2 during tumor metastasis, it serves as a foundational component for the development of antibody-drug conjugates (ADCs). A notable application of Sacituzumab is its conjugation with the cytotoxic drug, govitecan, to form Sacituzumab govitecan. This conjugate has demonstrated utility in the treatment of triple-negative breast cancer, highlighting its significant potential in therapeutic applications targeting this challenging oncological condition.

Citatuzumab is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target EpCAM (Epithelial Cell Adhesion Molecule), also known as TROP1 or CD326. This antibody comprises a human IgG1 type heavy chain and a human kappa (huκ) type light chain, with a predicted molecular weight of 145.4 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. Citatuzumab is applicable in research focused on cancer cell biology, particularly in studies investigating epithelial cell adhesion and metastasis.

Emapalumab (NI-0501) is a human monoclonal IgG1 antibody designed for the noncompetitive inhibition of interferon gamma (IFN-γ). It exhibits high binding affinity, with a dissociation constant (Kd) of 1.4 pM, to both free IFN-γ and IFN-γ that is bound to its receptor. This antibody is particularly useful in the study of hemophagocytic lymphohistiocytosis (HLH), providing a critical tool for research into the pathophysiology and potential therapeutic interventions for this condition.

Ebdarokimab (AK101) is a humanized IgG1-κ monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. This antibody is engineered for high specificity and affinity in targeting its designated antigens, ensuring effective application in therapeutic research.

Bivatuzumab (BIWA 4), a humanized monoclonal antibody, targets the CD44v6 isoform, a variant of the CD44 standard form. This antibody has been specifically developed for its potential role in targeting CD44v6, which is implicated in the progression of various sarcomas. Bivatuzumab is utilized in research focusing on chimeric antigen receptor (CAR)-redirected cytokine-induced killer (CIK) cells, providing a promising therapeutic approach for sarcoma treatment.

Leronlimab (PRO 140) is a humanized IgG4 monoclonal antibody targeting CCR5, a critical receptor involved in the entry of HIV-1 into cells and in the mediation of inflammatory processes. This antibody effectively inhibits HIV-1 viral entry and has demonstrated potential in reducing lung metastasis in mouse tumor models. Leronlimab is applicable for research in various fields including HIV, nonalcoholic steatohepatitis (NASH), and cancer, providing a versatile tool for investigating the role of CCR5 in disease progression and therapy.

Imzokitug is a humanized IgG1κ monoclonal antibody specifically targeting CKR-L1. For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

Miptenalimab (BI-754111) is a monoclonal antibody targeting human LAG-3 with a dissociation constant (K_D) of 88.6 nM. This antibody effectively inhibits the interaction between LAG-3 and its physiological ligand MHC class II, highlighting its potential utility in modulating immune responses in oncological and immunological research.

Miromavimab (M777-16-3) is a monoclonal antibody specifically targeting the ectodomain epitope G-II of the rabies virus strain ERAGP. This antibody is designed for precise binding and neutralization of the rabies virus, making it an essential tool for research in virology and infectious diseases.

The Anti-RGMC/HFE2 Antibody (DISC-0974) is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting RGMC/HFE2. This antibody is composed of a human IgG1 heavy chain and a kappa light chain, with a predicted molecular weight of 145.66 kDa. For isotype control purposes, reference should be made to the Human IgG1 kappa Isotype Control. This antibody is suitable for a range of research applications, focusing on the study of RGMC/HFE2 function and expression.

Levilimab (BCD-089) is a fully humanized monoclonal antibody that targets the interleukin-6 receptor (IL-6R), playing a crucial role in the modulation of inflammatory responses. This antibody is specifically designed for the study of inflammatory diseases, including rheumatoid arthritis, where IL-6R-mediated signaling is implicated in disease pathology and progression. Levilimab provides a valuable tool for researchers investigating the therapeutic potential of IL-6R inhibition in inflammation and autoimmune disorders.